NCBiotech News

Durham-based Ribometrix, a developer of small-molecule therapeutics that target ribonucleic acid (RNA), has raised $30 million in Series A financing.​​​​​​​

Pairwise, a gene editing and plant technology start-up, is establishing its headquarters in leased space on the Golden Belt Campus in the heart of downtown Durham.

The NIH's National Center for Advancing Translational Sciences has announced new SBIR and STTR funding opportunities for entrepreneurs aiming to commercialize innovations.

North Carolina’s entrepreneurial companies had an opportunity to learn more about alternative funding sources through the venture arms of disease foundations at "Invest in Cures," a Larger Than Life Science event series forum.

Deerfield Management, an investment management, information and philanthropy firm, has given the University of North Carolina at Chapel Hill an injection of up to $65 million to spur drug discovery and development.

Durham-based BioAgilytix, a fast-growing provider of bioanalytical testing services for large-molecule drugs, will be acquired by a privately held Belgian investment company.

Fortune 500 medical technology firm acquires Durham-based company and keeps manufacturing of biosurgical sealant device in North Carolina.

The challenge of developing new drugs to treat serious lower gastrointestinal disorders just got easier to digest for Symberix, a Durham biopharmaceutical company.

The road to better health is only a simple blood test away, thanks to a new consumer wellness package offered by Burlington-based global life sciences company LabCorp.

Advanced Animal Diagnostics (AAD) of Morrisville has entered into a license and commercialization agreement with Zoetis, the world’s largest animal-health company, to bring AAD’s mastitis-detection technology to dairy producers and veterinarians outside of the United States. 

Patients wanting easy access to their lab test results from LabCorp can now get them through their smart phones.

Precision health took center stage in North Carolina recently as Duke University hosted its second Precision Medicine World Conference (PMWC). The event attracted more than 400 experts who represented health and biotechnology organizations from around the world.

Humacyte, a Durham-based regenerative medicine company, has begun a Phase 2 clinical trial of Humacyl, its bioengineered blood vessel, in patients with vascular trauma.

RTI International -- a leading non-profit research institute in Research Triangle Park -- and Austin, Texas-based biotechnology company Asuragen have entered into a collaboration to look for a genetic disorder in North Carolina’s newborns.

Six North Carolina bioscience companies are among 15 companies from the Southeast selected as finalists for awards to be given at the 20th annual SEBIO Investor and Partnering Forum in Atlanta next month.